Vor Biopharma VOR Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $321.53M+245% | $93.31M-1.1% | $94.32M+46.1% | $64.55M+35.8% | ||
| $50.11M+79.8% | $27.88M-12.1% | $31.72M+9.9% | $28.87M+34.3% | ||
| $371.64M+207% | $121.19M-3.8% | $126.04M+34.9% | $93.42M+35.4% | ||
| $371.64M+207% | $121.19M-3.8% | $126.04M+34.9% | $93.42M+35.4% | ||
| -$371.64M-207% | -$121.19M+3.8% | -$126.04M-34.9% | -$93.42M-35.4% | ||
| $5.87M+37.4% | $4.27M-47.7% | $8.17M+517% | $1.32M+1,013% | ||
| —— | $4.27M-47.7% | $8.17M+517% | $1.32M+1,013% | ||
| —— | -$116.91M+0.8% | -$117.86M-28.0% | -$92.09M-33.7% | ||
| —— | -$17.69-911% | -$1.75+25.2% | -$2.34-8.8% | ||
| —— | -$17.69-911% | -$1.75+25.2% | -$2.34-11.4% | ||
| 148.1M+3.4% | 143.2M-46.6% | 268.1M+76.0% | 152.3M+17.6% | ||
| 148.1M+3.4% | 143.2M-46.6% | 268.1M+76.0% | 152.3M— | ||
| —— | -$116.82M+0.3% | -$117.17M-26.2% | -$92.86M-32.4% | ||
| $19K— | —— | $693K— | —— | ||
| —— | $0— | —— | —— | ||
| -$371.64M-207% | -$121.19M+3.8% | -$126.04M-34.9% | -$93.42M-35.4% | ||
| -$368.69M-214% | -$117.58M+4.0% | -$122.51M-34.8% | -$90.86M-34.4% | ||
| -$368.69M-214% | -$117.58M+4.0% | -$122.51M-34.8% | -$90.86M-34.4% | ||
| -$371.64M-207% | -$121.19M+3.8% | -$126.04M-34.9% | -$93.42M-35.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vor Biopharma profitable?
- Vor Biopharma is not currently profitable: it reported a net loss of $2.6B over the trailing twelve months.
- What is Vor Biopharma's earnings per share?
- Vor Biopharma's diluted EPS over the trailing twelve months is $-144.51.
- Where does Vor Biopharma's income statement data come from?
- Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.